Kevin Conroy is the Chairman, President, and Chief Executive Officer of Exact Sciences Corp, a leading provider of cancer screening and diagnostic tests. With a strong background in healthcare and diagnostics, Conroy has been instrumental in guiding the company's growth and success. He joined Exact Sciences in 2009 as the company's first CEO and has since led the organization through significant milestones, including the launch of Cologuard, a non-invasive stool-based DNA test for colorectal cancer screening. Prior to his role at Exact Sciences, Conroy held various leadership positions in the healthcare industry. He served as the President and CEO of Third Wave Technologies, a molecular diagnostics company, where he oversaw the development and commercialization of several diagnostic tests. Conroy also held executive positions at GE Healthcare, where he gained valuable experience in the medical device and diagnostics sectors. His extensive background in healthcare and diagnostics has been crucial in driving Exact Sciences' mission to help eradicate cancer through early detection and prevention. Under Conroy's leadership, Exact Sciences has grown into a market leader in cancer screening and diagnostics. He has been recognized for his contributions to the field, receiving numerous awards and accolades, including being named one of the "100 Most Influential People in Healthcare" by Modern Healthcare. Conroy's vision and strategic direction have been instrumental in the company's success, as evidenced by the widespread adoption of Cologuard and the development of a robust pipeline of innovative cancer screening and diagnostic tests. As Chairman, President, and CEO, Conroy continues to lead Exact Sciences in its mission to improve patient outcomes and save lives through early cancer detection.